Sign in

    Christopher PlahmTall Pines Capital

    Christopher Plahm's questions to Sanara Medtech Inc (SMTI) leadership

    Christopher Plahm's questions to Sanara Medtech Inc (SMTI) leadership • Q3 2024

    Question

    Christopher Plahm of Tall Pines Capital requested an update on the company's intellectual property progress with Cellerate and the commercial status of the BIASURGE product.

    Answer

    Executive Ronald Nixon stated that IP progress is a priority, is going very well, and that the company continues to file provisional patents. Executive Seth Yon reported that BIASURGE, which formally launched at the beginning of the year, is on pace with its scaling and facility-level approvals.

    Ask Fintool Equity Research AI